Prolium Bioscience Sclerosis, Lupus Treatment Studies Advancing

By Karen Roman

Prolium Bioscience, Inc. said it dosed its first patient in Phase 1/2 study of PRO-203, a T-cell engager treatment for systemic sclerosis, following the completion of a study in 20 healthy volunteers.

The company also completed the last patient and visit in a 26-week study of PRO-203 in treatment-refractory lupus nephritis patients, it stated.

Register for our weekly newsletter HERE

"Dosing the first patient with PRO-203 in systemic sclerosis marks an important milestone for Prolium as we advance our lead program in a disease with profound unmet medical need," said Scott Requadt, Prolium's CEO. "We plan to initiate additional studies of PRO-203 in multiple other autoimmune diseases in the near future."

READ MORE

Scales Tip to Small Business from Large Enterprise in IT Spend: Pax8 CEO Scott Chasin, Live from Pax8 Beyond 2026

Contact:

Exec Edge

[email protected]

Click HERE to follow us on LinkedIn

The post Prolium Bioscience Sclerosis, Lupus Treatment Studies Advancing appeared first on ExecEdge.

View Comments